Tandem Diabetes Care, Inc. (TNDM) |
| 17.08 0.79 (4.85%) 07-17 16:00 |
| Open: | 16.11 |
| High: | 17.1 |
| Low: | 15.91 |
| Volume: | 2,100,446 |
| Market Cap: | 1,170(M) |
| PE Ratio: | -15.53 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 20.10 |
| Resistance 1: | 17.20 |
| Pivot price: | 15.70 |
| Support 1: | 15.19 |
| Support 2: | 13.95 |
| 52w High: | 29.65 |
| 52w Low: | 9.98 |
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
| EPS | -1.370 |
| Book Value | 1.930 |
| PEG Ratio | 0.00 |
| Gross Profit | 8.236 |
| Profit Margin (%) | -9.20 |
| Operating Margin (%) | -7.05 |
| Return on Assets (ttm) | -3.7 |
| Return on Equity (ttm) | -65.7 |
Sat, 18 Jul 2026
Can Tandem Diabetes Care (TNDM) Turn Revenue Beats Into Durable Returns On Capital? - simplywall.st
Fri, 17 Jul 2026
Tandem Diabetes Care Inc (TNDM) Shares Surge 4.9% -- What GF Sco - GuruFocus
Fri, 17 Jul 2026
Form 4 Tandem Diabetes Care Inc For: 17 July By Investing.com - Investing.com Nigeria
Fri, 17 Jul 2026
Tandem Diabetes Care (TNDM) COO logs RSU vesting, 31,741 shares held after tax withholding - Stock Titan
Fri, 17 Jul 2026
Why Did TNDM Stock Jump 5% After Hours Despite Q4 Earnings Miss? - Stocktwits
Tue, 14 Jul 2026
Tandem Diabetes Care (TNDM) Expands Abbott Compatibility As Undervalued Narrative Faces A Fresh Test - Sahm
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |